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Abstract
Background: The Zimbabwean national prevention of mother-to-child HIV transmission (PMTCT) program provided
primarily single-dose nevirapine (sdNVP) from 2002–2009 and is currently replacing sdNVP with more effective antiretroviral
(ARV) regimens.
Methods: Published HIV and PMTCT models, with local trial and programmatic data, were used to simulate a cohort of HIV-
infected, pregnant/breastfeeding women in Zimbabwe (mean age 24.0 years, mean CD4 451 cells/mL). We compared five
PMTCT regimens at a fixed level of PMTCT medication uptake: 1) no antenatal ARVs (comparator); 2) sdNVP; 3) WHO 2010
guidelines using ‘‘Option A’’ (zidovudine during pregnancy/infant NVP during breastfeeding for women without advanced
HIV disease; lifelong 3-drug antiretroviral therapy (ART) for women with advanced disease); 4) WHO ‘‘Option B’’ (ART during
pregnancy/breastfeeding without advanced disease; lifelong ART with advanced disease); and 5) ‘‘Option B+:’’ lifelong ART
for all pregnant/breastfeeding, HIV-infected women. Pediatric (4–6 week and 18-month infection risk, 2-year survival) and
maternal (2- and 5-year survival, life expectancy from delivery) outcomes were projected.
Results: Eighteen-month pediatric infection risks ranged from 25.8% (no antenatal ARVs) to 10.9% (Options B/B+). Although
maternal short-term outcomes (2- and 5-year survival) varied only slightly by regimen, maternal life expectancy was reduced
after receipt of sdNVP (13.8 years) or Option B (13.9 years) compared to no antenatal ARVs (14.0 years), Option A (14.0
years), or Option B+ (14.5 years).
Conclusions: Replacement of sdNVP with currently recommended regimens for PMTCT (WHO Options A, B, or B+)i s
necessary to reduce infant HIV infection risk in Zimbabwe. The planned transition to Option A may also improve both
pediatric and maternal outcomes.
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Introduction
Antiretroviral drugs (ARVs) are highly effective for the prevention
of mother-to-child HIV transmission (PMTCT). Without ARV
prophylaxis, the risk of transmission by 18 months of age ranges from
25–40% in breastfeeding populations [1–3]. However, recent trials
have demonstrated that several ARV regimens, administered to
mothers and/or infants during pregnancy and breastfeeding, can
reduce transmission to 1–8% at 6–12 months of age [4–10]. The
World Health Organization (WHO) now recommends three-drug
antiretroviral therapy (ART) for all pregnant women with CD4 cells
,350/mL or clinical Stage 3–4 disease. For those with less advanced
disease, two options are recommended. ‘‘Option A’’ includes short-
course zidovudine during pregnancy and extended infant nevirapine
(NVP) prophylaxis throughout breastfeeding. ‘‘Option B’’ includes
maternal 3-drug ART during pregnancy and breastfeeding, with
cessation after weaning [11]. Select PMTCT programs in sub-
S a h a r a nA fr i c aa rei m p le m e n t i n gO p t i o nB ,a n da n‘‘ O p t i o nB +’’ has
also been proposed (lifelong ART for all pregnant, HIV-infected
women, regardless of CD4 cell count or disease stage) [12]. However,
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2010 guidelines by selecting Option A [12].
In 2009, only 53% of pregnant women identified as HIV-infected
worldwide received any ARVs for PMTCT, resulting in approxi-
mately 370,000 new infant infections [13]. Many of these women
received the ARV regimens previously recommended as a ‘‘mini-
mum’’ intervention by WHO: a single dose of nevirapine (sdNVP) to a
pregnant woman in labor and her infant after birth [13,14]. Although
inexpensive and relatively easy to administer, sdNVP is less effective
than currently recommended regimens (18-month transmission risks:
15–25%) [15–17] and can lead to drug-resistant virus that complicates
later therapy for both mothers and infected infants [18,19].
Zimbabwe is a low-income country where prolonged breast-
feeding is the norm [20,21]. The Zimbabwean Ministry of Health
and Child Welfare (MOHCW) has provided sdNVP through the
national PMTCT program since 2002, as one of the earliest
PMTCT programs in Africa [22]. In 2006–2007, the MOHCW,
with the Elizabeth Glaser Pediatric AIDS Foundation and the
Organization of Public Health Interventions and Development
Trust, demonstrated the feasibility of a pilot program providing
the antenatal/intrapartum component of the WHO Option A
regimen [23]. Our objective was to use simulation modeling to
evaluate the potential benefits to both infants and mothers of
replacing sdNVP with WHO 2010-recommended regimens on a
national scale in Zimbabwe.
Methods
Analytic overview
We linked two published computer simulation models to project
clinical outcomes of five PMTCT strategies in Zimbabwe. First, a
model of mother-to-child transmission (MTCT) during pregnancy
and delivery [24] was modified to incorporate each step of the
‘‘cascade’’ of PMTCT-related care, from first presentation at
antenatal care (ANC) through 18 months postpartum (Figure 1).
Second, the Cost-effectiveness of Preventing AIDS Complications
(CEPAC)-International model of adult HIV infection [25,26] was
used to project clinical outcomes for women following pregnancy,
and was expanded to simulate infant outcomes from birth through
the first two years of life. The models were linked by using CEPAC
results as MTCT model inputs (Text S1). Outcomes of the linked
models included risk of infant HIV infection at 4–6 weeks and 18
months of age and 2-year pediatric survival, as well as maternal 2-
year survival, maternal 5-year survival, and maternal life
expectancy after delivery. Additional details of model structure,
data inputs, sensitivity analyses, and results are presented in the
Appendix (Text S1).
Population and PMTCT strategies evaluated
We simulated a population of pregnant and breastfeeding women
in Zimbabwe who were HIV-infected at the time of conception [27].
For women identified as HIV-infected during ANC, five PMTCT
strategies were evaluated (Text S1): 1) A ‘‘no antenatal ARVs’’
strategy, for reference comparison; 2) a single-dose of nevirapine
(sdNVP) administered to laboring mothers and infants within 3 days
of birth, reflecting the 2002–2009 national Zimbabwe PMTCT
program and 2006 WHO ‘‘minimum’’ guidelines for resource-
constrained settings [14]; 3) WHO 2010 ‘‘Option A:’’ short-course
zidovudine during pregnancy and extended infant nevirapine during
breastfeeding for women with CD4 .350/mL and no evidence of
WHO stage 3–4 disease, with lifelong ART for women with
advanced disease [11]; 4) WHO 2010 ‘‘Option B:’’ ART through
pregnancy and breastfeeding regardless of CD4 or disease stage, with
continuation after weaning for women with advanced disease [11];
and 5) the ‘‘Option B+’’ under consideration in select locations:
lifelong ART for all pregnant, HIV-infected women, for comparison
[12,28]. ART-eligible women who linked to HIV-related healthcare
after delivery wereassumed to receive ART for their own health in all
strategies (Text S1). Mothers were assumed to breastfeed their infants
for a median duration of 18 months, based on Zimbabwean data
[21]. Throughout the manuscript, the term ‘‘ARV’’ refers to any
single or dual antiretroviral drug regimen used for PMTCT, while
‘‘ART’’ refers only to three-drug combination therapy (regardless if
used for PMTCT or for therapy of maternal disease).
Model structure
MTCT model. The MTCT model is a previously-published
decision-analytic simulation of a cohort of pregnant women from
conception through delivery [24] (TreeAgePro 2010 software,
Williamstown, MA). The model structure was expanded to include
key steps in antenatal care, as well as linkage to postnatal maternal
and pediatric care (Figure 1 and Text S1). Probabilities of HIV
transmission and maternal and infant death before and during
delivery were stratified by the severity of maternal HIV infection
(ART ‘‘eligible,’’ defined as WHO stage 3–4 disease or CD4 350/
,mL [11]; ‘‘not eligible;’’ or deceased) and by maternal receipt of
postnatal HIV care and ART.
CEPAC adult model. The CEPAC-International model is a
first-order Monte Carlo simulation of HIV infection, in which
patients are simulated individually from model entry through
death. Details of model structure and validation have been
published previously [25,26,29] and are further described in the
Appendix (Text S1). In brief, disease progression is characterized
by a sequence of monthly transitions between health states; these
include acute opportunistic and other infections prevalent in
Figure 1. ‘‘Cascade’’ of PMTCT and postnatal HIV care. Opportunities to maximize the effectiveness of PMTCT interventions may be lost at
each step in the pathway. ANC: antenatal care, ARVs: antiretroviral drugs, ART: antiretroviral therapy, sdNVP: single-dose nevirapine.
doi:10.1371/journal.pone.0020224.g001
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records all clinical events during each patient’s lifetime. A cohort
of ten million women is simulated to produce stable estimates of
outcomes (Text S1).
In the CEPAC adult model, current CD4 count, opportunistic
infection prophylaxis, and history or absence of previous
opportunistic infections determine the monthly risk of opportu-
nistic infections and HIV-related death (Table 1). HIV RNA
suppression with effective ART leads CD4 counts to increase,
reducing the risks for opportunistic infections and death. Before
initiation of ART or after virologic failure on ART, CD4 counts
decline at a rate determined by current RNA level; this is
accompanied by increased risks of opportunistic infections and
death. After planned interruption of suppressive ART at the time
of weaning (Option B only), CD4 counts decline more rapidly
based on data from ART interruption and PMTCT trials [30–32].
CEPAC infant model. A first-order, Monte Carlo simulation
model of infant HIV infection and survival was added to the CEPAC
model. Modeled infants enter the postnatal model at birth. Based on
events occurring before and during delivery in the MTCT model,
infants are assigned one of three HIV categories (HIV-unexposed;
HIV-exposed but uninfected; or HIV-infected) and three maternal
disease categories (HIV-uninfected; HIV-infected and ‘‘ART
eligible;’’ or HIV-infected and ‘‘ART non-eligible’’). Over a two-
year horizon, infants face a monthly probability of four key clinical
events: 1) maternal HIV infection, if mother was previously
uninfected, causing infants to transition from ‘‘unexposed’’ to
‘‘exposed-uninfected;’’ 2) maternal death, with risks derived from
Table 1. Selected model input parameters for a simulation model of strategies to prevent mother-to-child transmission of HIV in
Zimbabwe: Maternal data.
Variable Base Case Value
Range for sensitivity
analyses Data sources
Baseline maternal cohort characteristics
Age (mean (SD), in years) 24.0 (5) 20–30 MOHCW [27]
HIV prevalence 16% MOCHW [27]
HIV incidence 0.96%/year MOHCW [39]
Mortality during pregnancy 0.7% 0–2% MOHCW [27]
Live birth 95.7–98% 95–99% MOHCW [27]
Among HIV-infected women at first ANC visit:
CD4 count (mean (SD), cells/mL) 451 (50) ZVITAMBO trial [21] (SD: assumption)
ART eligible 275 (50) ZVITAMBO trial [21]
Not ART eligible 550 (50) ZVITAMBO trial [21]
Incident infection in pregnancy 664 (50) MACS [40]
Initial HIV RNA (mean copies/ml) 72,349 CTAC [41]
Access to PMTCT ‘‘cascade’’
Access to ANC 91% 80–100% MOHCW [27]
HIV testing in ANC 87% 58–95% MOHCW [23,39]
Receipt of HIV test result in ANC 99% 71–99% MOHCW [23,39]
Sensitivity of clinical assessment of ART eligibility 36% 20–50% MTCT-Plus Cohort [43]
Receipt of CD4 test result (Option A) 67% [79]
Delivery in health care facility 69% 50–100% MOHCW [23,39]
If HIV status negative/unknown, test in labor 36% MOHCW [23]
If HIV diagnosed in labor, receive sdNVP 80% MOHCW [23]
Postnatal HIV Care
Linkage to postnatal maternal care by 6 weeks postpartum 79% 51–100% Average and range: [36,44–48]
Loss to follow-up from postnatal maternal care 16% (year 1); 6%/year
(years 2+)
[37,80,81]
Maternal antiretroviral therapy
Efficacy (% HIV RNA suppression at 24 weeks)
1
st-line NVP/ZDV/3TC initiated in pregnancy 90% [50]
1
st-line NVP/d4T/3TC initiated post-partum
With sdNVP exposure 85% Difference between
sdNVP exposed and
unexposed: 0%–16%
OCTANE trial [49]
Difference: [18,69,71]
Without sdNVP exposure** 90% Difference assumed=5% [50]
2nd-line LPV/r/TDF/FTC 72% [82]
CD4 decline (6 months after ART interruption) 139 cells 75–139 cells/mL [30–32]
doi:10.1371/journal.pone.0020224.t001
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no longer at risk for HIV infection but are at higher risk of death due
to orphanhood [33,34]; 3) infant HIV infection through
breastfeeding, if infant was previously uninfected; and 4) infant
death from any cause. Risks of maternal death and of postnatal HIV
transmission are stratified by maternal disease stage and ARV
regimen, and risks of infant death are stratified by infant HIV
exposure/infection status and receipt of ART if infected.
HIV/AIDS care and ART. For HIV-infected infants, a one-
time probability of HIV diagnosis, linkage to HIV care, and ART
initiation was modeled [13]. For mothers, care and ART were
modeled in greater detail. A one-time probability of linkage to
maternal HIV care was incorporated; this parameter reflects the
probability that a post-partum mother will present to an HIV
clinic for her own healthcare by six weeks postpartum. Women not
linking to care within this period were assumed to present to HIV
care upon later development of a severe opportunistic infection.
Once in postnatal care for her own health, ART eligibility was
assumed to be assessed through both CD4 testing and clinical
evaluation. For women identified as ART-eligible, both ART and
trimethoprim/sulfamethoxazole prophylaxis were initiated
[13,35]. For women identified as not yet ART-eligible in
postnatal HIV care, medications were administered depending
on the modeled breastfeeding prophylaxis regimen: no
medications were dispensed for the ‘‘no antenatal ARVs’’ and
‘‘sdNVP’’ regimens; infant nevirapine syrup was dispensed for the
‘‘Option A’’ regimen; and maternal ART was dispensed for the
‘‘Option B’’ and ‘‘Option B+’’ regimens. Specific components of
3-drug ART regimens were simulated to reflect 2009 Zimbabwean
guidelines and common current practice in Zimbabwe (Text S1
and Table 1) [35]. ART monitoring and switching strategies are
also detailed in the Appendix (Text S1).
Loss to follow-up. During modeled ANC, women could be
lost to follow-up (LTFU) at any stage between first presentation
(booking) and delivery; if LTFU, no antenatal ARVs were
received, but the opportunity to access HIV testing and sdNVP
in labor remained. Women could also be LTFU between delivery
and six weeks postpartum [36], or after linkage to postnatal HIV
care [37,38]. In the absence of specific maternal or pediatric data
regarding monthly risks of LTFU and cessation of prophylactic
ARVs during breastfeeding, the impact of such events was
incorporated in sensitivity analyses via the highest published
postnatal transmission estimates for Options A, B and B+. For
HIV-infected infants, the impacts of loss to follow-up after
established pediatric HIV care were included in cohort-based
pediatric survival estimates.
Model input parameters
Maternal cohort characteristics and natural
history. Baseline maternal characteristics reflected cohorts of
pregnant women in Zimbabwe (Table 1 and Text S1). At first
ANC visit, mean age was 24.0 [27] and HIV prevalence was 16%
[39]; HIV incidence during pregnancy and breastfeeding was
0.96%/year [39]. Among HIV-infected women, mean CD4 was
275 cells/mL if ART-eligible [21], 550 cells/mL if not ART-eligible
[21], and 664 cells/mL if incidently infected during pregnancy
[40]. Because detailed clinical data to inform HIV disease
progression in the absence of ART were not available from
Zimbabwe, these natural history model inputs to the CEPAC
model were derived from a clinical cohort in South Africa (Text
S1) [41]. For women remaining HIV-negative, life expectancy was
projected using UNAIDS cause-deleted mortality rates [42].
Maternal access to care and ART. Modeled rates of access
to ANC, HIV and CD4 tests in ANC, ARV drugs for PMTCT,
and postnatal care reflected Zimbabwean national estimates
whenever available (Table 1). In the sdNVP strategy, women
were modeled to undergo clinical ART-eligibility assessment, but
not CD4 testing, and to initiate lifelong ART if WHO stage 3–4
disease was identified [11]. The sensitivity of clinical assessment for
ART eligibility was 36% [43]. In the base case analysis, to isolate
the benefits of each regimen, ARV medications were assumed to
be available for, accepted by, and adhered to by all women
diagnosed as HIV-infected in ANC, and CD4 testing (but not
result return) was assumed for all women under Option A. In
addition, sdNVP was modeled to be provided to 80% of women
newly HIV-diagnosed in labor [23,39].
The base-case rate of linkage to postnatal maternal HIV care
reflected the median of published values; in sensitivity analyses,
linkage rates ranged from 51–100%, depending on antenatal care
and PMTCT regimen received [36,44–48]. For women in HIV care
and receiving ART, the 24-week ‘‘efficacy’’ of first-line, NNRTI-
based maternal ART in suppressing HIV RNA to ,400 copies/ml
was 85% for women with previous sdNVP exposure [49] and 90%
(assumed difference of 5%) for women without exposure to sdNVP
[50]. In the six months following ART interruption at weaning
(Option B), CD4 count was modeled to decline by 139 cells [30,31].
Other modeled ART effects are described in Table 1.
Mother-to-child transmission risks. Mother-to-child HIV
transmission risks were derived from randomized clinical trials in
several African settings (Table 2) [1,4,5,8–10,15,17,21,51–61].
MTCT risks during the intrauterine and intrapartum period (by 4–
6 weeks of age) and postpartum period (6 weeks-18 months) were
stratified by maternal HIV stage and by PMTCT regimen received.
Postpartum transmission risks were additionally stratified by whether
breastfeeding during the first six months of life was exclusive (EBF) or
mixed (MBF, including any non-breastmilk liquid or solid) [62].
Pediatric outcomes. Mortality estimates for HIV-unexposed
children were derived from UNAIDS HIV-deleted mortality
estimates [42] and mortality rates for exposed-uninfected infants
were from the ZVITAMBO study in Zimbabwe [63] (Table 2).
Mortality rates for untreated HIV-infected children, stratified by
timing of HIV infection, were derived from a patient-level analysis
of 1,930 children from 12 African PMTCT trials, after removing
non-HIV-related causes of death [6]. ART was assumed available
for 36% of HIV-infected children [64]. Mortality rates for children
treated with ART were from a systematic review of pediatric ART
in Africa [65] and a pooled patient-level analysis from 16 African
cohorts [66]. For infants of any HIV infection or exposure status,
maternal death was assumed to increase mortality 2-fold [33].
Model validation and sensitivity analyses
Model results were validated by comparison to published values
(Text S1). Sensitivity analyses, described in detail in the Appendix
(Text S1), examined the impact of variations in key maternal
clinical and demographic characteristics, highest and lowest
published MTCT risks for each regimen, access to ANC and
HIV testing in ANC, linkage to postnatal HIV care, ART efficacy
and survival following sdNVP exposure, CD4 cell decline
following ART interruption, and pediatric and maternal non-
HIV-related mortality rates. Parameters leading to substantial
changes in model results were identified; a substantial change was
defined as 1) a change in the relative order of the outcomes of the
PMTCT regimens, or 2) a .10% relative change in the difference
between projected outcomes for each ARV regimen (example
provided in Text S1). In addition, we projected the impact of each
PMTCT regimen on infant infection risk for an annual cohort of
women becoming pregnant in Zimbabwe, including both HIV-
infected and HIV-uninfected women at conception (Text S1).
WHO 2010 PMTCT Guidelines in Zimbabwe
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Results
Base-case analyses (fixed levels of ARV uptake for PMTCT)
Pediatric outcomes. Among women HIV-infected at first
ANC visit, the risks of infant infection at 4–6 weeks of age were
projected to be 20.1% with no antenatal ARV prophylaxis,
10.8% with the 2002–2009 sdNVP-based national program, 7.2%
with Option A, and 5.4% with Option B and B+ (Table 3, top). At
18 months of age, cumulative risk of infant HIV infection ranged
from 25.8% (no antenatal ARVs) to 10.9% (Option B/B+). Two-
year pediatric survival similarly ranged from 78.4% (no antenatal
ARVs) to 84.9% (Option B/B+).
Maternal outcomes. Postpartum survival among HIV-
infected women was projected to range from 92.4% (no
antenatal ARVs, sdNVP) to 94.0% (Option B+) at two years,
and 79.8% (no antenatal ARVs, sdNVP) to 82.2% (Option B+)a t
Table 2. Selected model input parameters for a simulation model of strategies to prevent mother-to-child transmission of HIV in
Zimbabwe: Pediatric data.
II. Mother-to-child transmission risks
Base Case Value (Range for sensitivity analysis)
Maternal HIV status PMTCT regimen received
Intrauterine/intrapartum period (one-time risks)
No antenatal ARVs sdNVP* scZDV ART
Mother ART eligible
at conception
0.273 [52,83]
(0.199–0.322) [54,83,84]
0.176 [21,85]
(0.082–0.264) [15,17,86]
0.136 [5]
(0.091–0.157) [87,88]
0.033 [89]
(0.011–0.041) [10,58]
Mother not ART-eligible at
conception
0.175 [52,83]
(0.127–0.206) [54,83,84]
0.073 [21,85]
(0.033–0.109) [15,17,86]
0.036 [5]
(0.024–0.041) [8,88]
0.01 [10]
(0.004–0.028) [4,10]
Mother with incident infection
during pregnancy
0.30
(assumption)
0.20 (assumption) 0.16
(assumption)
0.033
(assumed=eligible)
Postnatal period (monthly risks, among infants HIV-uninfected at 4–6 weeks of age)
No postnatal ARVs Maternal ART Extended infant NVP
Mother ART eligible at conception 0.00758 (EBF) [21,85];
0.01278 (MBF) [21,85];
(0.00476–0.02336) [53,84]
0.00333[87]
(0–0.00534) [4,8,10]
n/a
Mother not ART-eligible at
conception
0.00238 (EBF) [85]; 0.00401 (MBF) [21]
(0.00149–0.00732) [53,60]
0.00189 (average:
[10,46,56,57])
(0–0.00534) [9,10]
0.00221 [9,61]
(0.00120–0.00311) [9,61]
Mother with incident infection
during pregnancy
0.00758 (EBF) [85];
0.01278 (MBF) [21,85];
(0.00476–0.02336) [53,84]
n/a n/a
III. Pediatric inputs
Variable Base Case Value Range for sensitivity analyses Data sources
Postnatal HIV Care
Probability of linking to pediatric
HIV diagnosis, care, and ART
36% 0–100% WHO [64]
Mortality risks One-year risk (%)
Two-year cumulative
risk (%)
HIV-unexposed children 5.4 5.9 [42]
HIV-exposed, uninfected children 7.4 9.2 [63]
HIV-infected children, no ART
Intrauterine/intrapartum infection 51.0 65.0 [6]
Postpartum infection 24.0 38.0 [6]
HIV-infected children, on ART 9.5 12.0 [65,90]
Relative increase in infant mortality
if maternal death occurs before 18 m
2-fold increase
(range: 1–6-fold increase)
[33,34]
SD: Standard deviation; MOHCW: Zimbabwe Ministry of Health and Child Welfare; MACS: Multicenter AIDS Cohort Study; CTAC: Cape Town AIDS Cohort; ANC: antenatal
care; ART: 3-drug, combination antiretroviral therapy; (sd)NVP: (single-dose) nevirapine; scZDV: short-course zidovudine; WHO: World Health Organization; ZDV:
zidovudine; 3TC: lamivudine; d4T: stavudine; LPV/r: lopinavir/ritonavir; TDF: tenofovir; FTC: emtricabine; EBF/MBF: exclusive/mixed breastfeeding.
*‘‘Without sdNVP exposure’’ refers to situations in which sdNVP was not received, or was received in combination with short-course zidovudine or other antenatal/
intrapartum medications which may decrease risk of NVP-associated NNRTI-resistant HIV [19].
doi:10.1371/journal.pone.0020224.t002
WHO 2010 PMTCT Guidelines in Zimbabwe
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20224five years after delivery (Table 3, bottom). The impacts of sdNVP-
associated resistance and ART interruption manifested primarily
after five years postpartum: projected life expectancy was slightly
lower following sdNVP (13.9 years) or Option B (13.9 years) than
following receipt of no antenatal ARVs or Option A (14.0 years).
Projected maternal life expectancy was greatest (14.4 years) with
lifelong universal ART (Option B+).
Sensitivity analyses
Sensitivity analyses were performed on all key model input
parameters and assumptions (Figures 2 and 3, Text S1). The model
input parameters with the greatest influence on pediatric and
maternaloutcomesareshownin Figure 2(Figure2a: 18-monthinfant
infection risk; Figure 2b: maternal life expectancy). Improvements in
HIV testing during pregnancy (2a and 2b: scenario 2), linkage to
postnatal care (2a and 2b: scenario 3), and reduction in the
proportion of women with CD4,350 (2a and 2b: scenario 4) as
might result through universal HIV screening acceptance and early
ART initiation prior to pregnancy) led to the greatest improvements
in both maternal and pediatric outcomes. Lowest published MTCT
risks for each regimen (2a: scenario 5) did not change the relative
order of the infant outcomes of the PMTCT regimens, but markedly
reduced overall transmission risks; lowest projected 18-month
infection risks ranged from 8.1% (sdNVP) to 4.5% (Option B/B+).
In the base case (Table 3), maternal life expectancy was slightly
shorter following receipt of sdNVP (13.8 years) than if no antenatal
ARVs were received for PMTCT (14.0 years). The maternal survival
and life expectancy differences between no antenatal ARVs and
sdNVP also depended on the degree to which sdNVP exposure was
assumed to reduce subsequent 1
st-line ART efficacy; at 0%
difference, the regimens led to equal maternal outcomes (Appendix);
at 16% difference, maternal outcomes associated with each strategy
differed substantially (Figure 2b, scenario 5). Base-case maternal life
expectancy was also shorter following receipt of Option B than if no
antenatal ARVs were received (Table 3). This result did not change
when a wide range of reported rates of CD4 decline after ART
interruption were incorporated (Appendix) [30–32].
Figure 3 depicts the impact of linkage to postnatal HIV care on
maternal life expectancy. In the base case, rates of linkage to
postnatal care were assumed to be equal following receipt of any
PMTCT regimen. As noted above, resulting maternal life
expectancies were slightly lower following the sdNVP and Option
B regimens than if no antenatal ARVs were received for PMTCT.
However, if the receipt of sdNVP or Option B improved rates of
linkage to postnatal care even slightly, compared to ANC without
receipt of antenatal ARVs for PMTCT (2.8% increase in linkage
for Option B, 3.8% increase for sdNVP), the negative impact of
these regimens on life expectancy was overcome.
All other parameters varied in sensitivity analyses are detailed in
the Appendix (Text S1). Notably, policy conclusions were
insensitive to variations in maternal age, risk of maternal mortality
due to pregnancy, probability of live infant birth, delivery location,
impact of sdNVP exposure on short-term infant outcomes, and
relative risk of infant mortality following maternal death.
Discussion
We linked two validated computer simulation models to project
clinical outcomes of improved PMTCT regimens in Zimbabwe.
These analyses simultaneously evaluate pediatric and maternal
outcomes, a novel approach for model-based investigations of HIV
care [67,68], and are likely applicable to other sub-Saharan Africa
settings where prolonged breastfeeding is common. Altogether,
pediatric outcomes, including HIV infection risk and survival,
would be markedly improved by replacing sdNVP-based programs
with 2010 WHO guideline-concordant regimens at fixed levels of
ARV uptake for PMTCT. However, it is worth noting that the
largest improvements in both pediatric and maternal survival may
result from a PMTCT program that offers lifelong ART to all
pregnant, HIV-infected women regardless of CD4 count or
Table 3. Outcomes of strategies to prevent mother-to-child HIV transmission in Zimbabwe: Base-case model results.
Model results
Pediatric outcomes (Infants born to women who are HIV-infected at conception)
Risk of HIV infection at 4–6
weeks of age (%)
Risk of HIV infection at 18
months of age (%)
2-year
survival (%)
No antenatal ARVs* 20.1 25.8 78.4
Single-dose NVP 10.8 17.2 81.9
Option A 7.2 12.8 83.5
Option B 5.4 10.9 84.9
Option B+ 5.4 10.9 84.9
Maternal outcomes after delivery (women who are HIV-infected at conception)
2-year
survival (%)
5-year
survival (%) Life expectancy (years)
No antenatal ARVs* 92.4 79.8 14.0
Single-dose NVP 92.4 79.8 13.8
Option A 92.5 79.9 14.0
Option B 93.7 80.0 13.9
Option B+ 94.0 82.2 14.5
*‘‘No antenatal ARVs’’ refers to the receipt of no medications for HIV therapy or for prevention of mother-to-child transmission during the antenatal period. Women who
link to postnatal HIV care are assumed to start ART after delivery if CD4 cell count is #350/mL or following development of a severe opportunistic infection.
doi:10.1371/journal.pone.0020224.t003
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PMTCT regimens, or 2) a .10% relative change in the difference between projected outcomes for each regimen. Panel 2a depicts parameters
influencing 18-month mother-to-child HIV transmission risk, and Panel 2b depicts parameters influencing maternal life expectancy from delivery;
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and already being considered for implementation in Malawi [12].
The choice of ARV regimen for PMTCT may have important
effects on maternal health, important not only in its own right, but
also for its impact on pediatric survival [33,34]. First, this analysis
underscores the potential long-term impact of sdNVP exposure.
The modeled impacts of ARV regimens that are received only
briefly during pregnancy or breastfeeding are small in comparison
to the impact of lifelong ART for women who link to postnatal
HIV care. Nonetheless, the sdNVP-associated life expectancy
reduction of 0.1 years is comparable in magnitude to the modeled
benefit of trimethoprim/sulfamethoxazole prophylaxis [25]. This
life expectancy reduction results from reduced virologic suppres-
sion on NNRTI-based ART due to sdNVP-associated NNRTI-
resistant virus. The difference in suppression among women with
and without sdNVP exposure determines the degree to which
sdNVP-based programs create a tradeoff between improved
pediatric outcomes and reduced maternal life expectancy. The
impact of sdNVP exposure may be negligible if sdNVP is received
.12–24 months prior to ART initiation [49,69–71]; in such cases,
scale-up of sdNVP-based PMTCT services will improve both
maternal and pediatric outcomes. However, absolute reductions in
24-week virologic suppression rates of 16–42% and 12–14% have
been reported for women initiating ART ,6 months and 6–12
months after sdNVP exposure, respectively [18,49,69] (base-case
value for this analysis: 5%). Because protease inhibitor-based first-
line ART is not widely available in many settings, the current
analysis lends strong support to efforts to expand non-sdNVP-
based PMTCT programs to improve both maternal and child
health.
In addition to the impact of sdNVP exposure, the ART
initiation and discontinuation strategies required by Option B may
also impact maternal health. Because ART is recommended for all
pregnant, HIV-infected in women in Option B, there may be a
health benefit from initiating ART at higher CD4 counts than
would prompt therapy in non-pregnant patients. However, it is not
yet known whether the adverse effects of ART discontinuation
after weaning will outweigh these benefits. When ART is
interrupted in men and non-postpartum women, marked increases
in viral load, inflammatory markers, and risk for both AIDS- and
non-AIDS-related events have been reported [30,72]. The current
analysis models rapid CD4 declines, ranging from 75–139 cells/
mL, in the 6 months following ART interruption at weaning in
Option B [30,32,72]; this results in a decrease in maternal life
expectancy of 0.6 years for women who interrupt ART at weaning
(then resume when later required for their own health), compared
Figure 3. Sensitivity analysis demonstrating the impact on maternal life expectancy of rates of linkage to postnatal HIV care. The
vertical axis represents maternal life expectancy, in years from delivery. The horizontal axis depicts the probability of linkage to postnatal HIV care for
women who receive the PMTCT regimens shown. This probability of linkage to care is varied from 79% (the base case value) to 85%. In the base case,
maternal life expectancy following the sdNVP and Option B regimens is lower than if no antenatal ARVs were received for PMTCT (triangles). This
occurs as a result of modeled negative impacts of sdNVP-associated resistance (sdNVP regimen) and ART interruption (Option B regimen). When the
probability of linkage to care following Option B is $81.8%, as indicated by the open arrow (2.8% more than if no antenatal ARVs are received), the
negative impact of ART interruption is overcome. Similarly, when the probability of linkage to care following sdNVP is $82.8%, as indicated by the
solid arrow (3.8% more than if no ARVs are received), the negative impact of sdNVP-associated resistance is overcome.
doi:10.1371/journal.pone.0020224.g003
these outcomes are shown on the vertical axes. Along the horizontal axes, each group of vertical bars represents a single scenario (numbered 1–6 in
2a and 1–5 in 2b), and each vertical bar represents a PMTCT regimen, as indicated.
doi:10.1371/journal.pone.0020224.g002
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from postpartum women, we do not specifically simulate
additional increased rates of non-AIDS-related events due to
interruption; if additional non-AIDS-related risks exist, the
negative impact of Option B will be greater than shown here.
Data on AIDS- and non-AIDS-related events among postpartum
women continuing or interrupting ART are anticipated in the next
several years [28], and will more accurately inform the risks and
benefits of Option B versus Option B+.
These analyses also highlight that linkage to postnatal maternal
HIV care, and thus initiation of ART when needed, is the step in
the PMTCT ‘‘cascade’’ that most dramatically influences
maternal life expectancy. The impact of improved linkage to care
on maternal life expectancy is greater than that of improved access
to ANC or HIV testing (holding linkage rates constant for those in
care and diagnosed), or any specific PMTCT regimen during
pregnancy. Because published rates of linkage to postnatal care
range widely and are rarely stratified by PMTCT regimen
received [46,47], model-based analyses can highlight areas for
future research. For example, if women who receive sdNVP- or
Option B-based PMTCT interventions are even slightly more
likely to register in postnatal HIV care than are women who
receive ANC but no medications for PMTCT (3–4% absolute
increases in linkage rates), the life expectancy benefits of this
improvement in linkage outweigh the negative effects of sdNVP-
associated resistance and ART interruption. However, if receipt of
these regimens does not improve linkage to postnatal care
compared to ANC services alone, there may be an important
tradeoff between long-term maternal and pediatric health with
expansion of sdNVP- or Option B- based programs.
Although linkage to postnatal care was the access-to-care
parameter with the greatest individual influence on maternal life
expectancy, improved uptake at each step in a ‘‘cascade’’ of
PMTCT care (including access to ANC, HIV testing and result
receipt, and availability and acceptance of ARVs [73]; Figure 1)
confers substantial benefits for both infant and maternal health. In
fact, improvements in two dimensions are critical: both replace-
ment of sdNVP with more effective regimens and improved uptake
of any given PMTCT regimen. While the current analysis
addresses the first dimension in greatest detail, further analyses
examining the clinical impacts, costs, and cost-effectiveness of
interventions to improve uptake are also needed.
This analysis has two main limitations. First, when detailed
clinical data to inform modeled maternal and pediatric HIV
disease progression were not available from Zimbabwe, data from
surrounding southern African countries were used instead. Base-
case clinical risks for HIV-infected mothers, such as risks of
opportunistic infections and tuberculosis, were derived from South
Africa, and might reasonably be expected to be similar in
neighboring Zimbabwe. Similarly, risks of MTCT, after stratifi-
cation by maternal CD4, PMTCT regimen received, and
breastfeeding duration, might also be anticipated to be similar
across Southern African settings. The impacts of non-Zimbab-
wean data were tested in extensive sensitivity analyses, as detailed
in the Appendix (Text S1), and had little impact on model results.
Second, life expectancy projections are subject to uncertainty
about events occurring over long time horizons, as healthcare
systems and HIV therapy may change substantially in the distant
future. Because of the uncertainty inherent in long-term
projections, we also report similar findings based on the short-
term outcomes of MTCT risks, 2-year pediatric survival, and 2-
year and 5-year maternal survival.
Model-projected clinical outcomes are not intended to be
interpreted in isolation, but rather as one component of a decision-
making framework that incorporates many factors, including
feasibility, affordability, and equity. Implementation of more
effective PMTCT regimens will be resource-intensive; costs will
include not only drug costs, but also infrastructure, personnel, and
training costs for clinics and laboratories. However, the 2010-
recommended PMTCT regimens may also save money in the
future by averting not only costly care for pediatric HIV infection
[74], but also the costly morbidity and mortality associated with
delayed maternal ART initiation [26,75] or sdNVP-associated
resistance [29]. Model-based analyses of pediatric outcomes have
suggested that ART for PMTCT is very cost-effective in many
settings, compared to sdNVP or to no ARVs [76–78]. Additional
budgetary impact and cost-effectiveness analyses, comparing
Option A to Option B and incorporating short-term and long-
term benefits and costs for both mothers and infants, will comprise
an important area of future research. In the interim, model-based
analyses can assist policymakers to understand the clinical
tradeoffs anticipated to result from the replacement of sdNVP
with more effective PMTCT regimens.
Conclusions
Replacing sdNVP with currently WHO-recommended PMTCT
regimens at a fixed level of ARV uptake for PMTCT will improve
both maternal and pediatric health outcomes in Zimbabwe. The best
currently available data suggest that continued dependence on
sdNVP-based programs would impact positively on pediatric health,
but may worsen long-term maternal outcomes, unless also accom-
panied by expanded access to postnatal HIV care and ART for
eligible women. To avoid an untenable tradeoff between maternal
and child health, additional resources are needed to implement
WHO guideline-concordant PMTCT programs (Options A, B, or
possibly B+) in resource-constrained settings, including Zimbabwe.
Supporting Information
Text S1 The Appendix reports additional details of technical
model structure, input data parameters, and model results,
including extensive model validation and sensitivity analyses.
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